Drugs / KVD001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02193113 | Jul 2014 → Jun 2015 | diabetic macular edema | KalVista Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03466099 | Feb 2018 → Oct 2019 | diabetic macular edema | KalVista Pharmaceuticals, Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KVD001 | “KVD001” NCT03466099 ↗ |
| Action | Inhibit | “A novel plasma kallikrein inhibitor” NCT02193113 ↗ |
| Route | Intravitreal | “administered by intravitreal (IVT) injection” NCT02193113 ↗ |